Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 2/3 2Phase 4 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 46Head & Neck 7Endocrine 2Breast 2Tumor-Agnostic 1Thoracic 1NET 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 2Fluorouracil 2Everolimus 2trametinib 1toripalimab 1fosbretabulin 1fluorocholine 1dabrafenib 1combretastatin 1cobimetinib 1anlotinib 1Water 1Vemurafenib 1Testosterone 1Temozolomide 1Somatostatin 1Sodium Iodide 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Radiofrequency Ablation 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1PE regimen 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Injections 1Erythromycin 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Fluorouracil × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT03992911 2019-06-20

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Peking University

Phase 2/3 Unknown
336 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡